| |
|
|
|
Wellcome Trust Genome Campus, Hinxton, UK
1-4 May 2007
Advances in genomics and molecular genetics have made an enormous contribution to understanding the pathogenesis of human disease. Exploitation of this knowledge has opened up new avenues of research where the genes and pathways altered in human disease can be reproduced in animal “humanised” models. These systems have enormous potential not only in the development of new strategies for disease prevention but also for the validation of new drug targets and for drug efficacy screening. These models also provide an experimental approach to understanding the relative role of environment versus genetic factors in disease aetiology – a research area that is almost intractable with other current experimental models. In addition, the genes that have evolved to protect animals from the environment can exhibit marked species differences in their functions, level of expression and regulation. This can often lead to great difficulty in extrapolating drug safety data obtained as part of drug development in animals to man. An approach to circumvent some of these problems is the generation of models that have been “humanised” for these metabolic pathways. It is the aim of this ESF-WT Conference to report and discuss some of the outstanding advances that have recently been made in modelling human disease and foreign compound metabolism and how these models can be applied to disease prevention and to the development of new drug therapies.
|
|
|
|
|
|
|
|
Organized by:
|
|
European Science Foundation (ESF) & Wellcome Trust (WT) |
|
|
Invited Speakers:
|
|
R. Bailing, GBF Braunschweig, DE - S. Bhattacharya, WTCHG, UK - N. Coppeland, IMCB Singapore, SG - R. Cox, MRC Harwell, UK - L. Fisher, UCL London, UK - J. Flint, Oxford U., UK - R. Fodde, Erasmus MC Rotterdam, NL - F. Gonzalez, NCI Bethesda, US - K. Hunter, NIH Bethesda, US - M. Manz, IRB Bellinzone, CH - L. Neyses, Manchester U., UK - D. Porteous, Edinburgh U., UK - N. Rosenthal, EMBL Monterotondo Scalo, IT - D. Rubinsztein, CIMR Cambridge, UK - L. Schultz, The Jackson Lab. Bar Harbor, US - H. Thomas, Imperial College London, UK - F. Walsh, Wyeth Pharmaceuticals, US - R. Wolf, Dundee U., UK.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2 March 2007
|
|
|
|
|
|
|
|
Registration:
|
|
2 March 2007
|
|
|
E-mail:
|
|
corefice@esf.org
|
|
|
|
|
|
|
|
|